Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fortunato Ciardiello
Observed name:
F. Ciardiello
Institution:
University of Campania "Luigi Vanvitelli"
Observed institutions:
University of Campania "Luigi Vanvitelli",
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
ORCID:
0000-0002-4661-5540
Observed ORCID:
0000-0002-4661-5540
OpenAlex ID:
A5031051525
Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma
2026
·
Ugo Chianese
, Chiara Papulino
, et al.
·
Signal Transduction and Targeted Therapy
·
14
PDF
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
2025
·
D. Ciardiello
, L. Boscolo Bielo
, et al.
·
ESMO Open
·
14
PDF
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
2025
·
A. Gravina
, P. Gargiulo
, et al.
·
ESMO Open
·
12
PDF
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3
2026
·
S. Kopetz
, J. Tabernero
, et al.
·
Annals of Oncology
·
9
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling
2026
·
Giulia Martini
, Stefania Napolitano
, et al.
·
Nature Reviews Clinical Oncology
·
8
SO-32 Entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis
2022
·
I. Garrido-Laguna
, S. Lonardi
, et al.
·
Annals of Oncology
·
8
Association between neutropenia and efficacy in patients with refractory mCRC receiving trifluridine/tipiracil + bevacizumab: post hoc analysis of the SUNLIGHT trial
2025
·
G.W. Prager
, E. Elez
, et al.
·
ESMO Gastrointestinal Oncology
·
6
PDF
Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients
2026
·
Luisa Amato
, Ines Tavoletta
, et al.
·
Translational Oncology
·
2
Increased Vegf-C Serum Levels are Predictive of a Poor Outcome in Patients with Resectable Gastric Cancer
2014
·
M.M. Laterza
, M. Orditura
, et al.
·
Annals of Oncology
·
2
Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies
2026
·
D. Ciardiello
, G. Martini
, et al.
·
ESMO Gastrointestinal Oncology
·
1
82P Using imaging biomarkers to predict antiangiogenic efficacy in pretreated metastatic colorectal cancer (mCRC)
2026
·
A. Nicastro
, M.C. Brunese
, et al.
·
Annals of Oncology
·
1
PDF
164TiP PROCEADE-CRC-03: A phase III study of precemtabart tocentecan (Precem-TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC)
2026
·
K. Raghav
, J. Taieb
, et al.
·
Annals of Oncology
·
1
PDF
71P Early- versus late-onset RAS wild-type (RASWT) metastatic colorectal cancer (mCRC) patients receiving first-line (1L) anti-EGFR therapy: A pooled ctDNA analysis of three clinical trials
2026
·
V. Martelli
, J. Vidal Barrull
, et al.
·
Annals of Oncology
·
1
PDF
Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report
2026
·
Vincenzo Terrano
, Erica Perri
, et al.
·
International Cancer Conference Journal
·
1
PDF
36P BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6
2025
·
T. Yoshino
, S. Kopetz
, et al.
·
Annals of Oncology
·
1
PDF
Pc.01.5 Gut Microbiota Correlates With Antitumor Activity in Patients With Mcrc and Nsclc Treated With Cetuximab Plus Avelumab
2023
·
M. Romeo
, G. Iadanza
, et al.
·
Digestive and Liver Disease
·
1
Consensus recommendations for the management of locally advanced rectal cancer
2026
·
R.-D. Hofheinz
, R. Garcia-Carbonero
, et al.
·
ESMO Gastrointestinal Oncology
100P Determinants of response to atezolizumab–bevacizumab (atezo–bev) in metastatic colorectal cancer (mCRC): Insights from the Motricolor CT3 trial
2026
·
C. Vaghi
, F.J. Ros Montana
, et al.
·
Annals of Oncology
PDF
7RO Molecular correlates of enhanced outcome with first-line (1L) encorafenib + cetuximab (EC) ± mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BREAKWATER study
2026
·
S. Kopetz
, K.N. Shah
, et al.
·
Annals of Oncology
PDF
61P Neoadjuvant ipilimumab, nivolumab, and high-dose vitamin C in pMMR/MSS colon cancer: Results of the ALFEO pilot study
2026
·
A. Amatu
, F.M. Tosi
, et al.
·
Annals of Oncology
PDF
165TiP Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line treatment in circulating tumor DNA–selected metastatic colorectal cancer (ROMANCE trial)
2026
·
G. Pellizzari
, M.G. Zampino
, et al.
·
Annals of Oncology
PDF
448eP Chemoradiotherapy enhances anti-tumor immune response in non-NE SCLC models blocking ITGB1/FN1-mediated EMT
2026
·
L. Amato
, C. de Rosa
, et al.
·
ESMO Open
PDF
456P NK cell heterogeneity is associated with chemoimmunotherapy response in small cell lung cancer patients
2026
·
C. de Rosa
, F. Somma
, et al.
·
ESMO Open
PDF
457P Investigation of lurbinectedin-induced cytosolic DNA/RNA sensors activation and immune cell-mediated cytotoxicity in small cell lung cancer
2026
·
S. Capaldo
, C. de Rosa
, et al.
·
ESMO Open
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer
2026
·
V. De Falco
, P.P. Vitiello
, et al.
·
ESMO Gastrointestinal Oncology
Show more works
View as search
Works count:
33
Citation count:
82
H-index:
6
I10-index:
3
Year
Topic
Type